On November 20, GE Healthcare revealed plans to buy medical imaging software firm Intelerad in a $2.3 billion all-cash deal aimed at strengthening its foothold in outpatient healthcare markets.
The deal gives GE HealthCare, whose equipment are prominent in hospitals, access to Intelerad’s cloud-based medical imaging software and other solutions that are used by outpatient care clinics.
Intelerad is a leading medical imaging software and digital enterprise workflow solutions company with a significant presence in outpatient ambulatory care settings. Its cloud-first products are designed for radiology and cardiology and extend across both inpatient and outpatient care settings.
GE Healthcare is an American multinational medical technology company headquartered in Chicago, Illinois. It was spun off from General Electric (GE) on January 4, 2023, with GE retaining 13.5% ownership. GE HealthCare provides digital infrastructure, data analytics and decision support tools designed to help in the diagnosis, treatment and monitoring of patients.
Evercore is serving as exclusive financial advisor and Sidley Austin LLP as deal counsel to GE Healthcare. For Intelerad, UBS Investment Bank is serving as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP as deal counsel.
The transaction is expected to be completed in the first half of 2026, subject to customary closing conditions and regulatory approvals. GE HealthCare intends to fund this transaction with cash on hand and proceeds from debt financing.
According to data captured in the LevinPro HC database, this transaction marks the 122nd Laboratories, MRI and Dialysis transaction of the year, and the 65th in the diagnostic subsector. Throughout all of 2024, there were 121 Laboratories, MRI and Dialysis transactions, 64 of them in the diagnostic subsector.
This deal follows GE Healthcare’s purchase of Belgium-based Icometrix in September 2025. Icometrix is a healthcare technology company that develops imaging analysis technology for neurological disorders, including Alzheimer’s disease. Terms for that deal were not disclosed.
